Bailey Gregory

Director Bailey Gregory bought 400,000 shares of BHVN at $7.50 (Nov 13); stock now $8.27, down -83.6% from 52-week high of $50.36.

Bailey Gregory, a Director, purchased 400,000 shares at $7.50 on 2025-11-13, increasing his holdings by 24.7% to 2.02M shares. The stock has declined sharply: it stands at $8.27 today, representing a -83.6% drop from its 52-week high of $50.36, and has fallen -48.2% over the past 30 days. Biohaven is unprofitable, with net income of $-173.4M for the full fiscal year and a market cap of $875.4M. Critically, Gregory's historical track record at BHVN shows poor timing: of his four prior buys at this ticker, only 1 of 4 was well-timed at the 90-day mark, with an average 90-day return across those trades of -5.5%. The current purchase coincides with a cluster buy pattern—3 other insiders also bought within the past 14 days—yet this cluster activity occurs during a period of severe stock depreciation and fundamental unprofitability, making it difficult to draw a confidence signal from the timing alone.

Director Bailey Gregory bought 3.9K shares of SER at $4.59 on 2024-12-17; stock now at $5.53, up 10.6% in 30 days but down 62.8% from 52-week high.

Bailey Gregory purchased 3,866 shares at $4.59, adding 6.1% to his holdings. The transaction timing follows recent volatility: the stock has gained 10.6% over the past 30 days but remains significantly depressed at -62.8% from its 52-week high of $14.87. Critically, Gregory's prior trades at SER show a mixed track record—only 1 of 5 prior buys generated positive 90-day returns, with three consecutive August-September 2024 purchases largely underwater at the 90-day mark. The company itself presents a mixed fundamental picture: while annual revenue growth reached +317.6%, it remains unprofitable on a full-year basis, with the latest quarter showing only $14,000 in revenue against a $49.2M market cap. This purchase occurs within the context of poor historical execution on this specific ticker and deteriorating full-year profitability, making it insufficient to signal conviction absent additional catalyst visibility.

Director Bailey Gregory buys 5,000 BHVN shares at $44.19 on 2024-09-24; stock up +18.5% in 30 days, +40.3% in 90 days post-transaction.

Bailey Gregory, a director at Biohaven Ltd., purchased 5,000 shares at $44.19 for a total value of $220,966.00 on 2024-09-24, adding to holdings of 1,620,071 shares post-transaction. The stock has appreciated significantly since the purchase, trading +18.5% over the subsequent 30 days and +40.3% over 90 days, with current price at $49.23. Among Gregory's prior trades at BHVN (4 distinct transactions), the timing pattern is mixed: two of four prior buys showed positive 90-day returns (the 2024-05-13 buy posted +13.8%, and the 2023-10-04 buy posted +85.8%), while two showed negative 90-day outcomes. However, this recent purchase was made into a company carrying a net loss of $-319,771,000.00 across its most recent full fiscal year, warranting scrutiny of the underlying business fundamentals alongside the positive stock momentum.

Director Bailey Gregory bought 1,137 shares of SER at $6.03 on 2024-09-20; stock down 49.6% from 52-week high.

Bailey Gregory, a director at Serina Therapeutics, purchased 1,137 shares at $6.03 on 2024-09-20, increasing his holdings from 62,240 to 63,377 shares. This transaction occurs as the stock trades 49.6% below its 52-week high of $14.87 and has declined 10.8% over the prior 30 days. Gregory's prior trades at this ticker show a pattern of negative near-term returns: his four prior buys at SER (most recent on 2024-08-16) posted 30-day returns of -11.9%, -24.2%, -27.8%, and subsequent outcomes remain unmeasurable. Across his broader cross-ticker trading history, his 19 prior buys averaged -1.6% at 30 days and -2.4% at 90 days, with a 90-day win rate of 18.18%. The company reported annual revenue growth of +317.6% but remains unprofitable on a full-year basis despite posting a $5.2M net income in the latest quarter—a sign of potential volatility in underlying business performance.

Director Bailey Gregory bought 14,388 shares over 2 days for $88,257.39; holdings grew 30.1%, but stock down 55.5% YoY and -19.2% in 30 days.

Bailey Gregory purchased 2 separate tranches totaling 14,388 shares for $88,257.39 on 2024-09-18 and 2024-09-19 at prices of $6.23 and $6.11 respectively, increasing his holdings by 30.1%. However, the context reveals headwinds: the stock currently trades at $6.62, down 55.5% from its 52-week high of $14.87 and down 19.2% over the past 30 days. Gregory's prior trades at this ticker (5 previous buys) have shown consistently negative 30-day returns, ranging from -3.2% to -27.8%, with 0 of 0 prior same-ticker buys well-timed at the 90-day mark. The company generated $51,000 in latest-quarter revenue and reported $5,204,000 net income, but was unprofitable on a full-year basis, creating uncertainty about fundamental sustainability despite 317.6% annual revenue growth.

Director Bailey Gregory bought 1,776 shares of SER at $8.25 on 2024-08-20; stock down 45.2% from 52-week high, yet he purchased for fourth consecutive day

Bailey Gregory purchased 1,776 shares at $8.25 on 2024-08-20, marking his fourth consecutive buy at Serina Therapeutics within the past week (purchases on 2024-08-19, 2024-08-16, 2024-08-15, and 2024-08-14). The stock currently trades at $8.15, down 45.2% from its 52-week high of $14.87 and down 14.1% over the past 30 days, suggesting a sustained price decline. His cross-ticker track record shows mixed results: 15 prior buys averaged 4.6% return over 30 days but only 2.5% over 90 days with a 25% win rate, indicating his timing at other securities has not been strong. At Serina specifically, only one prior trade outcome is measurable (a May 2024 buy with +0.8% after 30 days), and his prior same-ticker purchases remain too recent to assess outcomes. The accumulation pattern in the final week of August during pronounced weakness warrants observation as the company navigates year-over-year revenue growth of 317.6% while reporting negative annual net income.

Director Bailey Gregory bought 19,200 shares of SER in 3 transactions (Aug 15-19) for $140,116.48, raising holdings 72.2% to 45,806 shares

Bailey Gregory, a Director, executed 3 separate purchases totaling 19,200 shares for $140,116.48 at prices ranging from $6.65 to $7.93, lifting his post-transaction holdings to 45,806 shares from 26,606 shares (a 72.2% increase). The timing occurred as the stock traded near its 52-week low of $6.42, with the stock currently at $8.25, representing a -44.5% decline from its 52-week high of $14.87 and a -15.0% drop over the prior 30 days. While Serina Therapeutics has demonstrated remarkable annual revenue growth of +317.6%, the company remains unprofitable on a full-year basis despite a positive quarterly net income of $5.2M on revenue of $51.0K. The multi-transaction structure and substantial increase in stake during a period of significant stock weakness warrant investor attention to both the company's underlying business trajectory and the insider's conviction in current valuation levels.

Director Bailey Gregory bought 6,400 shares at $7.07; stock now $7.14, down 52.0% from 52-week high of $14.87.

Bailey Gregory, a director, purchased 6,400 shares at $7.07 on 2024-08-14, increasing holdings by 31.7% to 26,606 shares total. The purchase occurs after substantial recent price decline: the stock is down 33.9% in 30 days and 52.0% from its 52-week high of $14.87, now trading at $7.14. Serina Therapeutics has demonstrated rapid revenue growth at +317.6% year-over-year and achieved a $5.2M net income in the latest quarter, yet the company was unprofitable on a full-year basis. Gregory's timing on prior trades at this ticker has been mixed—his 5 prior SER purchases show outcomes ranging from -9.9% to +0.8% at the 30-day mark, with limited 90-day data—and his cross-ticker buy pattern shows 50% accuracy at 90 days. The accumulation during a period of sharp decline warrants monitoring against subsequent price recovery and company operational progress.